Grapefruit Products Interactions

Grapefruit products should be avoided due to CYP3A4 inhibition, which increases abemaciclib exposure and toxicity risk.

Source: NLP:abemaciclib

May increase axitinib plasma concentrations and should be avoided.

Source: NLP:axitinib

Grapefruit may inhibit CYP3A and increase ceritinib exposure. Do not consume grapefruit or grapefruit juice during treatment.

Source: NLP:ceritinib

Strong CYP3A4 inhibitor increases erlotinib exposure, raising risk of exposure-related toxicity. Avoid co-administration or reduce erlotinib dosage if unavoidable.

Source: NLP:erlotinib

Strong CYP3A4 inhibitor that increases erlotinib exposure and risk of exposure-related toxicity. Avoid concomitant use.

Source: NLP:erlotinib hydrochloride

CYP3A inhibitor that may increase nifedipine exposure. Careful monitoring and dose adjustment necessary; consider lowest dose.

Source: NLP:nifedipine

Strong CYP3A inhibitor. Increases nirogacestat exposure, which may increase risk of adverse reactions.

Source: NLP:nirogacestat

Food or drink containing grapefruit should be avoided during treatment with JOURNAVX. Grapefruit inhibits CYP3A, increasing suzetrigine exposure.

Source: NLP:suzetrigine

Grapefruit may increase exposure of cabozantinib, increasing risk of exposure-related adverse reactions. Avoid coadministration or reduce CABOMETYX dosage.

Source: NLP:cabozantinib

Grapefruit increases exposure to colchicine. Advise patients to avoid grapefruit when taking colchicine.

Source: NLP:colchicine tablets 0.5 mg

Grapefruit products contain CYP3A inhibitors that increase entrectinib concentrations. Avoid grapefruit products during treatment.

Source: NLP:entrectinib

Contains strong or moderate CYP3A inhibitors. Should be avoided during ibrutinib treatment to prevent increased ibrutinib concentrations.

Source: NLP:ibrutinib

CYP3A4 inhibitor may decrease metabolism of ifosfamide to its active alkylating metabolites, potentially decreasing effectiveness of ifosfamide treatment.

Source: NLP:ifosfamide

Avoid consumption of grapefruit or Seville oranges during lonafarnib therapy due to CYP3A inhibition.

Source: NLP:lonafarnib

Grapefruit is a moderate CYP3A inhibitor. Concomitant use increases rilzabrutinib exposure and risk of adverse reactions.

Source: NLP:rilzabrutinib